![Elizabeth Elizabeth Kwong](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Postes actifs de Elizabeth Elizabeth Kwong
Sociétés | Poste | Début | Fin |
---|---|---|---|
Giiant Pharma, Inc.
![]() Giiant Pharma, Inc. BiotechnologyHealth Technology Giiant Pharma, Inc. is a Canadian preclinical-stage biotech company that specializes in designing gut-restricted small molecule drug therapeutics with various biological targets in gastroenterology. The company is based in Montréal, Canada and was founded by Elizabeth Elizabeth Kwong. The company's proprietary precision delivery technology platform allows for the creation of tissue-specific drugs with improved tolerability and enhanced therapeutic effects. Giiant's first lead program, GT-2108, is a microbiota-activated PDE4 inhibitor prodrug. Maxime Ranger has been the CEO of the company since 2021. | Fondateur | - | - |
Corporate Officer/Principal | - | - |
Historique de carrière de Elizabeth Elizabeth Kwong
Statistiques
Internationale
Canada | 2 |
Opérationnelle
Founder | 1 |
Corporate Officer/Principal | 1 |
Sectorielle
Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 1 |
---|---|
Giiant Pharma, Inc.
![]() Giiant Pharma, Inc. BiotechnologyHealth Technology Giiant Pharma, Inc. is a Canadian preclinical-stage biotech company that specializes in designing gut-restricted small molecule drug therapeutics with various biological targets in gastroenterology. The company is based in Montréal, Canada and was founded by Elizabeth Elizabeth Kwong. The company's proprietary precision delivery technology platform allows for the creation of tissue-specific drugs with improved tolerability and enhanced therapeutic effects. Giiant's first lead program, GT-2108, is a microbiota-activated PDE4 inhibitor prodrug. Maxime Ranger has been the CEO of the company since 2021. | Health Technology |
- Bourse
- Insiders
- Elizabeth Elizabeth Kwong
- Expérience